Company intelligence / Profile preview
Persica Pharmaceuticals
Canterbury, Kent, United Kingdompersicapharmaceuticals.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Positive Phase 1b clinical data for PP353 announced in March 2025. The trial met its primary endpoint and demonstrated statistically significant, clinically meaningful, and durable reduction in pain and disability in patients with chronic Low Back Pain with Modic Type 1 changes, with meaningful reductions in pain from 3 months up to at least 12 months[4][10].
- Therapeutic areas
- Rheumatology
- Modalities
- Small molecules (antibiotic formulation)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Persica Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Persica Pharmaceuticals.